Aphria Inc. announced that it has received its European Union Good Manufacturing Practices certification in respect of medicinal products for human use and investigational medicinal products for human use, from the Malta Medicines Authority ("MMA") at the Company's subsidiary, ARA - Avanti Rx Analytics. Aphria selected the MMA to perform the EU GMP audit as the criteria and certification thresholds established by the MMA are among the most stringent and demanding in the EU. The certification will allow the Company to ship bulk and finished dried flower, as well as bulk and finished cannabis oil for medicinal use in permitted jurisdictions throughout the European Union. Aphria's German operations have been preparing for the importation of EU-GMP certified cannabis from Canada, allowing for shipments to the Company's German subsidiary CC Pharma GmbH in order to leverage CC Pharma's expansive in-country distribution network. The Company anticipates that its first shipments of medical cannabis to CC Pharma will occur in its fourth quarter of its fiscal 2020.